Xiaoling Ling

525 total citations
20 papers, 281 citations indexed

About

Xiaoling Ling is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Xiaoling Ling has authored 20 papers receiving a total of 281 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 10 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Xiaoling Ling's work include Cancer-related Molecular Pathways (5 papers), Epigenetics and DNA Methylation (4 papers) and RNA modifications and cancer (4 papers). Xiaoling Ling is often cited by papers focused on Cancer-related Molecular Pathways (5 papers), Epigenetics and DNA Methylation (4 papers) and RNA modifications and cancer (4 papers). Xiaoling Ling collaborates with scholars based in China and Canada. Xiaoling Ling's co-authors include Da Zhao, Bingxue Yan, Xiaoming Hou, Xiangjin Li, Xingxu Zhao, Fei Su, Yongbin Lu, Xiaoying Xu, Xin Liu and Jie Hao and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Oncogene.

In The Last Decade

Xiaoling Ling

19 papers receiving 278 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaoling Ling China 10 178 124 62 34 32 20 281
Negin Taghehchian Iran 12 248 1.4× 174 1.4× 54 0.9× 29 0.9× 46 1.4× 33 320
Chan Joo Yeom Japan 8 171 1.0× 157 1.3× 62 1.0× 28 0.8× 25 0.8× 9 290
Congya Zhou China 10 199 1.1× 141 1.1× 106 1.7× 45 1.3× 11 0.3× 22 356
Xiaobo Zhao China 8 159 0.9× 105 0.8× 96 1.5× 18 0.5× 20 0.6× 16 275
Zining Jin China 11 186 1.0× 136 1.1× 74 1.2× 61 1.8× 8 0.3× 28 309
Rujuan Bao China 8 257 1.4× 150 1.2× 92 1.5× 40 1.2× 12 0.4× 10 367
Chuanliang Xu China 9 152 0.9× 76 0.6× 69 1.1× 86 2.5× 18 0.6× 17 298
David T. Hoang United States 5 114 0.6× 64 0.5× 76 1.2× 113 3.3× 47 1.5× 7 256
Maoguang Ma China 5 215 1.2× 172 1.4× 82 1.3× 30 0.9× 111 3.5× 6 345
Zhixiang Zhuang China 9 106 0.6× 74 0.6× 59 1.0× 34 1.0× 20 0.6× 35 227

Countries citing papers authored by Xiaoling Ling

Since Specialization
Citations

This map shows the geographic impact of Xiaoling Ling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoling Ling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoling Ling more than expected).

Fields of papers citing papers by Xiaoling Ling

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoling Ling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoling Ling. The network helps show where Xiaoling Ling may publish in the future.

Co-authorship network of co-authors of Xiaoling Ling

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoling Ling. A scholar is included among the top collaborators of Xiaoling Ling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoling Ling. Xiaoling Ling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ling, Xiaoling, et al.. (2024). A biologically inspired fluorescent probe with enhanced sensing performance for detection of Al3+ based on metal replacement strategy. Microchemical Journal. 203. 110904–110904. 3 indexed citations
2.
Zhu, Kaili, et al.. (2024). TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress. Molecular Biology Reports. 51(1). 205–205. 13 indexed citations
3.
Han, Qingxin, Ruirui Sun, X.Q. Wang, et al.. (2024). The self-assembly of polyacrylic acid nanoparticles induced by non-covalent interactions enhances the response of molecular fluorescent probes to formaldehyde. Journal of Materials Chemistry C. 13(5). 2459–2469. 2 indexed citations
4.
Yang, Jingru, Yongbin Lu, Yi Xiao, et al.. (2023). USP10 promotes the progression of triple-negative breast cancer by enhancing the stability of TCF4 protein. Biochemical Pharmacology. 218. 115864–115864. 4 indexed citations
5.
6.
7.
Teng, Yuee, Huiping Li, Lili Zhang, et al.. (2023). Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial. BMC Medicine. 21(1). 300–300. 9 indexed citations
8.
Yan, Min, Tao Sun, Xiaoling Ling, et al.. (2023). Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive metastatic breast cancer: Final results from the phase 2 ICU trial.. Journal of Clinical Oncology. 41(16_suppl). 1042–1042. 1 indexed citations
9.
Lu, Yongbin, Yi Xiao, Jingru Yang, et al.. (2022). TRIM65 Promotes Malignant Cell Behaviors in Triple‐Negative Breast Cancer by Impairing the Stability of LATS1 Protein. Oxidative Medicine and Cellular Longevity. 2022(1). 4374978–4374978. 10 indexed citations
10.
Ma, Yan, Haibo Zhang, Cheng Chen, et al.. (2022). TRIM32 promotes radioresistance by disrupting TC45-STAT3 interaction in triple-negative breast cancer. Oncogene. 41(11). 1589–1599. 14 indexed citations
11.
Zhang, Tao, Fei Su, Yongbin Lu, et al.. (2022). MYC/MAX-Activated LINC00958 Promotes Lung Adenocarcinoma by Oncogenic Transcriptional Reprogramming Through HOXA1 Activation. Frontiers in Oncology. 12. 807507–807507. 9 indexed citations
12.
13.
14.
Ling, Xiaoling, et al.. (2021). Diagnosis and Individualized Treatment of Three Primary Malignant Tumors: A Case Report. Breast Cancer Targets and Therapy. Volume 13. 519–527. 3 indexed citations
15.
16.
Lu, Yongbin, Gang Yang, Yi Xiao, et al.. (2020). Upregulated cyclins may be novel genes for triple-negative breast cancer based on bioinformatic analysis. Breast Cancer. 27(5). 903–911. 23 indexed citations
17.
Ling, Xiaoling, et al.. (2019). MicroRNA-138-5p inhibits cell migration, invasion and EMT in breast cancer by directly targeting RHBDD1. Breast Cancer. 26(6). 817–825. 56 indexed citations
18.
19.
Shi, Xiangqun, et al.. (2014). Down-regulation of thyroid hormone receptor β1 gene expression in gastric cancer involves promoter methylation. Biochemical and Biophysical Research Communications. 444(2). 147–152. 7 indexed citations
20.
Xu, Xiaoying, et al.. (2009). Aberrant methylation of the THRB gene in tissue and plasma of breast cancer patients. Cancer Genetics and Cytogenetics. 196(2). 140–145. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Negin Taghehchian Breakdown of academic impact, for papers by Chan Joo Yeom Breakdown of academic impact, for papers by Congya Zhou Breakdown of academic impact, for papers by Xiaobo Zhao Breakdown of academic impact, for papers by Zining Jin Breakdown of academic impact, for papers by Rujuan Bao Breakdown of academic impact, for papers by Chuanliang Xu Breakdown of academic impact, for papers by David T. Hoang Breakdown of academic impact, for papers by Maoguang Ma Breakdown of academic impact, for papers by Zhixiang Zhuang
Rankless by CCL
2026